NR
Vice President, Business Development
Get the full picture
Sign in to uncover key details.
Engeneic
Manufacturing · Australia · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Bldg 53, L 4 11 Julius Ave, North Ryde, ...Website
www.engeneic.comRevenue
$5.2 MillionIndustry
About Engeneic
EnGeneIC is a clinical-stage biotech company focused on developing the EDV™ nanocell platform, which delivers targeted cancer therapies directly to tumors while activating the immune system. Their pioneering approach combines cancer cell killing with immune cell activation, making it a first-in-class cyto-immunotherapy platform. The company aims to address challenging cancers such as pancreatic cancer and recurrent glioblastoma with customizable treatment options. EnGeneIC's innovative technology positions it at the forefront of precision cancer care.Explore more
Engeneic Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Engeneic
Compare insights from companies similar to Engeneic, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Engeneic Tech Stack
A closer look at the technologies used by Engeneic
See more technologies
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Engeneic
Sign Up For FreeTo access detailed company insights
EnGeneIC is a clinical-stage biotech company focused on developing the EDV™ nanocell platform, which delivers targeted cancer therapies directly to tumors while activating the immune system. Their pioneering approach combines cancer cell killing with immune cell activation, making it a first-in-class cyto-immunotherapy platform. The company aims to... Read More
